Evolving options for the treatment of cluster headache.
Journal
Current opinion in neurology
ISSN: 1473-6551
Titre abrégé: Curr Opin Neurol
Pays: England
ID NLM: 9319162
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
27
3
2020
medline:
29
1
2021
entrez:
27
3
2020
Statut:
ppublish
Résumé
Cluster headache is a neurological disorder that patients consider the most severe pain they experience. Recognizing new treatments provides opportunities to advance current management. In contrast to the classic treatments, new options narrow in on the therapeutic target and are better tolerated. Calcitonin gene-related peptide (CGRP) pathway blockade with monoclonal antibodies (MABs), specifically the CGRP MAB galcanezumab, represents an important advance for episodic cluster headache, reducing the number of attacks during a bout. Neuromodulation strategies aimed at anatomical structures involved in the pathophysiology of cluster headache, such as the sphenopalatine ganglion and the vagus nerve, have proved effective in reducing the pain intensity and the number of attacks, and also to be safe and well tolerated. Our understanding of the pathophysiology of cluster headache and its management continues to grow. Novel treatments have appeared from research, such as neuromodulation and CGRP monoclonal antibodies. Nonetheless, chronic cluster headache and designing trials that select the correct sham in evaluating devices remain challenging.
Identifiants
pubmed: 32209808
doi: 10.1097/WCO.0000000000000808
pii: 00019052-202006000-00011
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Calcitonin Gene-Related Peptide Receptor Antagonists
0
galcanezumab
55KHL3P693
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
323-328Références
Hoffmann J, May A. Neuromodulation for the treatment of primary headache syndromes. Expert Rev Neurother 2019; 19:261–268.
Schor LI. Cluster headache: investigating severity of pain, suicidality, personal burden, access to effective treatment, and demographics among a large international survey sample. Cephalalgia 2017; 37: 172 (1S):172.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38:1–211.
Irimia P, Cittadini E, Paemeleire K, et al. Unilateral photophobia or phonophobia in migraine compared with trigeminal autonomic cephalalgias. Cephalalgia 2008; 28:626–630.
Headache Classification Committee of the International Headache. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33:629–808.
Barloese M, Lund N, Petersen A, et al. Sleep and chronobiology in cluster headache. Cephalalgia 2015; 35:969–978.
Lund NL, Snoer AH, Jennum PJ, et al. Sleep in cluster headache revisited: results from a controlled actigraphic study. Cephalalgia 2019; 39:742–749.
Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 2017; 97:553–622.
May A, Leone M, Afra J, et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol 2006; 13:1066–1077.
Robbins MS, Starling AJ, Pringsheim TM, et al. Treatment of cluster headache: the American Headache Society evidence-based guidelines. Headache 2016; 56:1093–1106.
Fogan L. Treatment of cluster headache. A double-blind comparison of oxygen v air inhalation. Arch Neurol 1985; 42:362–363.
Cohen AS, Burns B, Goadsby PJ. High-flow oxygen for treatment of cluster headache: a randomized trial. JAMA 2009; 302:2451–2457.
Schindler EAD, Wright DA, Weil MJ, et al. Survey analysis of the use, effectiveness, and patient-reported tolerability of inhaled oxygen compared with injectable sumatriptan for the acute treatment of cluster headache. Headache 2018; 58:1568–1578.
Evers S, Rapoport A, Soc IH. The use of oxygen in cluster headache treatment worldwide: a survey of the International Headache Society (IHS). Cephalalgia 2017; 37:396–398.
Geerlings RP, Haane DY, Koehler PJ. Rebound following oxygen therapy in cluster headache. Cephalalgia 2011; 31:1145–1149.
Petersen AS, Barloese MC, Lund NL, Jensen RH. Oxygen therapy for cluster headache. A mask comparison trial. A single-blinded, placebo-controlled, crossover study. Cephalalgia 2017; 37:214–224.
The Sumatriptan Cluster Headache Study Group. Treatment of acute cluster headache with sumatriptan. N Engl J Med 1991; 325:322–326.
Ekbom K, Monstad I, Prusinski A, et al. The Sumatriptan Cluster Headache Study Group. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. Acta Neurol Scand 1993; 88:63–69.
Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 2004; 44:414–425.
Rapoport AM, Mathew NT, Silberstein SD, et al. Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study. Neurology 2007; 69:821–826.
Cittadini E, May A, Straube A, et al. Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study. Arch Neurol 2006; 63:1537–1542.
Ambrosini A, Vandenheede M, Rossi P, et al. Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: a double-blind placebo-controlled study. Pain 2005; 118:92–96.
Leroux E, Valade D, Taifas I, et al. Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2011; 10:891–897.
Goadsby PJ, Holland PR. An update: pathophysiology of migraine. Neurol Clin 2019; 37:651–671.
Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes: prolonged effects from a single injection. Pain 2006; 122:126–129.
Gonen M, Balgetir F, Aytac E, Tasci I, Demir CF, Mungen B. Suboccipital steroid injection alone as a preventive treatment for cluster headache. J Clin Neurosci. 2019;68:140–5.
May A, Schwedt TJ, Magis D, et al. Cluster headache. Nat Rev Dis Primers 2018; 4:18006.
Bussone G, Leone M, Peccarisi C, et al. Double blind comparison of lithium and verapamil in cluster headache prophylaxis. Headache 1990; 30:411–417.
Wei DY, Khalil M, Goadsby PJ. Managing cluster headache. Pract Neurol 2019; 19:521–528.
Matharu MS, van Vliet JA, Ferrari MD, Goadsby PJ. Verapamil induced gingival enlargement in cluster headache. J Neurol Neurosurg Psychiatry 2005; 76:124–127.
Lanteri-Minet M, Silhol F, Piano V, Donnet A. Cardiac safety in cluster headache patients using the very high dose of verapamil (>/=720 mg/day). J Headache Pain 2011; 12:173–176.
Cohen AS, Matharu MS, Goadsby PJ. Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. Neurology 2007; 69:668–675.
Steiner TJ, Hering R, Couturier EG, et al. Double-blind placebo-controlled trial of lithium in episodic cluster headache. Cephalalgia 1997; 17:673–675.
Jammes JL. The treatment of cluster headaches with prednisone. Dis Nerv Syst 1975; 36:375–376.
Leone M, Dodick D, Rigamonti A, et al. Topiramate in cluster headache prophylaxis: an open trial. Cephalalgia 2003; 23:1001–1002.
Christman DS, Faubion MD. Suicide attempt following initiation of topiramate. Am J Psychiatry 2007; 164:682–683.
Ozturk B, Ovunc Ozon A, Karadas O. Evaluation of cognitive functions in migraineurs treated with topiramate. J Clin Neurosci 2019; 59:89–92.
Leone M, D’Amico D, Moschiano F, et al. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia 1996; 16:494–496.
Pringsheim T, Magnoux E, Dobson CF, et al. Melatonin as adjunctive therapy in the prophylaxis of cluster headache: a pilot study. Headache 2002; 42:787–792.
Nesbitt AD, Marin JC, Tompkins E, et al. Initial use of a novel noninvasive vagus nerve stimulator for cluster headache treatment. Neurology 2015; 84:1249–1253.
Moller M, Schroeder CF, May A. Vagus nerve stimulation modulates the cranial trigeminal autonomic reflex. Ann Neurol 2018; 84:886–892.
Goadsby PJ. Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. Lancet Neurol 2002; 1:251–257.
Akerman S, Simon B, Romero-Reyes M. Vagus nerve stimulation suppresses acute noxious activation of trigeminocervical neurons in animal models of primary headache. Neurobiol Dis 2017; 102:96–104.
Contreras RJ, Beckstead RM, Norgren R. The central projections of the trigeminal, facial, glossopharyngeal and vagus nerves: an autoradiographic study in the rat. J Auton Nerv Syst 1982; 6:303–322.
Gaul C, Diener HC, Silver N, et al. Noninvasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): a randomised controlled study. Cephalalgia 2016; 36:534–546.
de Coo IF, Marin JC, Silberstein SD, et al. Differential efficacy of noninvasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: a meta-analysis. Cephalalgia 2019; 39:967–977.
Silberstein SD, Mechtler LL, Kudrow DB, et al. Non-invasive vagus nerve stimulation for the ACute Treatment of Cluster Headache: findings from the randomized, double-blind, sham-controlled ACT1 study. Headache 2016; 56:1317–1332.
Goadsby PJ, de Coo IF, Silver N, et al. Noninvasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: a randomized, double-blind, sham-controlled ACT2 study. Cephalalgia 2018; 38:959–969.
Goadsby PJ. Sphenopalatine (pterygopalatine) ganglion stimulation and cluster headache: new hope for ye who enter here. Cephalalgia 2013; 33:813–815.
May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 1999; 19:115–127.
Sluder G. The role of the sphenopalatine (or Meckle's) ganglion in nasal headache. New York Med J 1908; 87:989–990.
Devoghel JC. Cluster headache and sphenopalatine block. Acta Anaesthesiol Belg 1981; 32:101–107.
Felisati G, Arnone F, Lozza P, et al. Sphenopalatine endoscopic ganglion block: a revision of a traditional technique for cluster headache. Laryngoscope 2006; 116:1447–1450.
Meyer JS, Binns PM, Ericsson AD, Vulpe M. Sphenopalatine gangionectomy for cluster headache. Arch Otolaryngol 1970; 92:475–484.
Narouze S, Kapural L, Casanova J, Mekhail N. Sphenopalatine ganglion radiofrequency ablation for the management of chronic cluster headache. Headache 2009; 49:571–577.
Ibarra E. Neuromodulation of sphenopalatine ganglion to alleviate the symptoms of cluster headache: a case report. Boletín El Dolor 2007; 46:12–18.
Ansarinia M, Rezai A, Tepper SJ, et al. Electrical stimulation of sphenopalatine ganglion for acute treatment of cluster headaches. Headache 2010; 50:1164–1174.
Schoenen J, Jensen RH, Lantéri-Minet M, et al. Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-controlled study. Cephalalgia 2013; 33:816–830.
Goadsby PJ, Sahai-Srivastava S, Kezirian EJ, et al. Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial. Lancet Neurol 2019; 18:1081–1090.
Jürgens TP, Barloese M, May A, et al. Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache. Cephalalgia 2017; 37:423–434.
Barloese MCJ, Jürgens TP, May A, et al. Cluster headache attack remission with sphenopalatine ganglion stimulation: experiences in chronic cluster headache patients through 24 months. J Headache Pain 2016; 17:67.
Barloese M, Petersen A, Stude P, et al. Sphenopalatine ganglion stimulation for cluster headache, results from a large, open-label European registry. J Headache Pain 2018; 19:6.
Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 1994; 117 (Pt 3):427–434.
Fanciullacci M, Alessandri M, Figini M, et al. Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 1995; 60:119–123.
Vollesen ALH, Snoer A, Beske RP, et al. Effect of infusion of calcitonin gene-related peptide on cluster headache attacks: a randomized clinical trial. JAMA Neurol 2018; 75:1187–1197.
Goadsby PJ. Primary headache disorders: five new things. Neurol Clin Pract 2019; 9:233–240.
Goadsby PJ, Dodick DW, Leone M, et al. Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med 2019; 381:132–141.
Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 2018; 91:e2211–e2221.
Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 2018; 38:1442–1454.
Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 2018; 75:1080–1088.
Lipton RB, Diener HC, Barbanti P, et al. Efficacy and safety of fremanezumab for the prevention of episodic cluster headache: results of a randomized, double-blind, placebocontrolled, phase 3 study. Cephalalgia 2019; 39:358–359.
Dodick DW, Goadsby PJ, Lucas C, et al. Phase 3 randomized trial of galcanezumab in chronic cluster headache: double-blind treatment. Cephalalgia 2019; 39:46–47.
Freund B, Kotchetkov IS, Rao A. The efficacy of botulinum toxin in cluster headache: a systematic review. J Oral Facial Pain Headache 2019.
Weatherall MW, Nandi D. Percutaneous electrical nerve stimulation (PENS) therapy for refractory primary headache disorders: a pilot study. Br J Neurosurg 2019; 33:608–612.
Kelderman T, Vanschoenbeek G, Crombez E, Paemeleire K. Safety and efficacy of percutaneous pulsed radiofrequency treatment at the C1-C2 level in chronic cluster headache: a retrospective analysis of 21 cases. Acta Neurologica Belgica 2019; 119:601–605.
Miller S, Lagrata S, Matharu M. Multiple cranial nerve blocks for the transitional treatment of chronic headaches. Cephalalgia 2019; 39:1488–1499.
Rubio-Beltran E, Labastida-Ramirez A, Villalon CM, MaassenVanDenBrink A. Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther 2018; 186:88–97.
Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 2010; 30:1159–1169.
Snoer A, Vollesen ALH, Beske RP, et al. Calcitonin-gene related peptide and disease activity in cluster headache. Cephalalgia 2019; 39:575–584.
D’Amico D, Leone M, Ferraris A, et al. Role of nitric oxide in cluster headache. Ital J Neurol Sci 1999; 20: (2 Suppl): S25–S27.
Hoffmann J, Goadsby PJ. New agents for acute treatment of migraine: CGRP receptor antagonists, iNOS inhibitors. Curr Treat Options Neurol 2012; 14:50–59.
Straube A, Ellrich J, Eren O, et al. Treatment of chronic migraine with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): a randomized, monocentric clinical trial. J Headache Pain 2015; 16:543.